The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den

Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 –

Pharming’s first Phase II clinical trial for Pompe’s disease finalised, showing survival, skeletal muscle regeneration and overall improvement of heart

New York University Medical Center Frank Martiniuk, Ph.D. A collaborative effort to test animal models with enzyme and gene replacement

Applied Biological Sciences Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified